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In medicinal chemistry ﬁeld, the biochemical pathways, involved in 7-transmembrane domains G-protein coupled receptors
(GPCRs) activation, are commonly studied to establish the activity of ligands towards GPCRs. The most studied steps are the
measurement of activated GTP-α subunit and stimulated intracellular cAMP. At the present, many researchers deﬁned agonist
or antagonist activity of potential GPCRs drugs employing [35S]GTPγSo r[ 3H]cAMP as probes. Recently, the corresponding
lanthanide labels Eu-GTP and Eu-cAMP as alternative to radiochemicals have been developed because they are highly sensitive,
easy to automate, easily synthesized, they display a much longer shelf-life and they can be used in multilabel experiments. In the
present review, the receptor-drug interaction by europium employment for studying the biochemical pathway of GPCR activation
hasbeen focused.Moreover,comparative studiesbetween lanthanide labelprobes andthecorrespondingradiolabeled compounds
have been carried out.
Copyright © 2007 Colabufo Nicola Antonio et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Luminescence is deﬁned as emitted radiation by a chemical
species, molecule, or atom. It occurs when an electron re-
turns to the electronic ground state from an excited state,
loosing its excess energy as a photon. Electronic states of or-
ganic molecules can be grouped into singlet and triplet state.
The singlet state is characterized by the presence of all the
electrons with their spins paired, while the triplet state dis-
plays one set of the electron spin unpaired (see Figure 1).
The phosphorescence and ﬂuorescence light emissions
are the main phenomena belonging to luminescence (see
Figure 2).
Phosphorescence occurs when the excited electron in the
singlet state undergoes intersystem crossing to a metastable
triplet state and then to the electronic ground state with
the emission of a photon. Since this phenomenon originates
from the lowest triplet state, it shows a decay time approxi-
mately equal to the lifetime of the triplet state (from 10−4 to
10 seconds). Therefore, phosphorescence is often character-
ized by an afterglow which is not observed for ﬂuorescence.
Fluorescence occurs when the molecule returns to the
electronic ground state from the excited singlet state by emis-
sion of a photon and the lifetime of an excited singlet state is
approximately from 10−9 to 10−7 seconds. To date, many bi-
ological and medical applications are based on ﬂuorescence
properties of pharmacological tools. These compounds per-
mit to visualize single step activated in cell biochemical path-
ways, to estimate changes in functional and structural prop-
erty cells, and to appreciate the modiﬁcation of their molec-
ular complexes involved in biological systems.
Indeed, the ﬂuorescence spectroscopy is one of the most
important applications for monitoring the molecular inter-
actions at the single molecule level and now widely used in
biological research.
In particular, the receptor-ligand interaction study,
which represents the starting point of drug discovery in
medicinal chemistry ﬁeld, could be better performed by2 Metal-Based Drugs
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Figure 1: Singlet states (all electrons in the molecule are spin-
paired) and triplet states (one set of electron spins is unpaired) in
excited molecules.
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Figure 2: Possible physical process following absorption of a pho-
ton by a molecule; A = absorption; F = ﬂuorescence; P = phospho-
rescence; processes involving photons = continue arrows; Radiation-
less transitions (v = vibrational relaxation, i = intersystem crossing,
c = internal conversion) = dotted arrows.
ﬂuorescence resonance energy transfer (FRET) and biolumi-
nescence resonance energy transfer (BRET) techniques.
At the present, this study is carried out employing radi-
oligands that display some limitations due to the safety, the
storage, the handling, and the disposal of radioactive mate-
rials; other limitations are due to the diﬃculties to perform
analysis in living cells. The development of lanthanide-based
assays to assess receptor-ligand interactions is improving the
characterization and the evaluation of potential new drugs
and pharmacological tools discovery [1–3].
Lanthanidelabelsareanalternativetoradiochemicalsbe-
cause they are highly sensitive, easy to automate, easily syn-
thesized, they display a much longer shelf life, and can be
used in multilabel experiments.
In the present review, the receptor-drug interaction by
europium employment for studying the biochemical path-
w a yo fG P C Ra c t i v a t i o nw i l lb ef o c u s e d .
The lanthanide series comprises the 15 elements with
atomic number 57 through 71 as depicted in Figure 3.T h e
complexes of some lanthanides such as Samarium (Sm3+),
Europium (Eu3+), Terbium (Tb3+), and Dysprosium (Dy3+)
areknowntobeluminescent;theirionsemitﬂuorescentlight
of speciﬁc wavelengths when coordinated to speciﬁc ligands.
The lanthanide ions in solutions or in complex possess lu-
minescence properties because of the transitions within 4f-
shell. The excitation of lanthanide ions occurs at the expense
of the intramolecular energy transfer from excited organic
molecule to lanthanide ion. The sensitization of lumines-
cence of lanthanide ions in complexes with organic ligand
allows their application as luminescence probes to establish
the structure and the properties of biological objects.
The major advantages of lanthanide labels are (i) ul-
trasensitive and speciﬁc signal, (ii) low background, (iii)
amenability to automation, as well as (iv) stability and safety.
The speciﬁc signal from the lanthanide is due to the long
lifetime of the excited state that can be temporally sepa-
rated from the nonspeciﬁc signal [1–5]. Typical lifetimes of
background ﬂuorescence from plates, reagents, or cells are
ranging from picoseconds to microseconds [6, 7] while lan-
thanide lifetimes are from 0.2 to 1.5 milliseconds. Thus, the
excitedstateoflanthanidesislonglived.Thisgivestheadvan-
tage of being able to excite the label, to delay measurement
of the emission signal until the background ﬂuorescence has
completely decayed, and then to collect the speciﬁc emission
signal from the lanthanide. This delay period leads to an ul-
trasensitive and speciﬁc signal which can be time averaged.
Lanthanides excitation occurs in the ultraviolet region
while the emission is in the visible spectrum as depicted in
Table 1.
The emitted light is at a longer wavelength (lower en-
ergy) than the absorbed light since some of the energy is
lost because of the vibrations; the diﬀerence in wavelenght
between positions of the band of the excitation and emis-
sion is termed Stokes’ shift as depicted in Figure 4. The large
Stokes’ shift (greater than 200nm) of the lanthanide ions
contributes to the low background signal since there is mini-
mal crosstalk between excitation and emission signals. In ad-
dition, the emission peak is very sharp allowing tight limits
for the excitation ﬁlter sets. These features make this method
amenable to use with multiple labels, since Eu, Sm, Dy, and
Tb have diﬀerent excitation and emission proﬁles and dif-
ferent decay times. Hence, multiple assays can be performed
in a single well, thus greatly reducing the number of time
and reagents needed. Finally, not less important is the safety
of ﬂuorescent probes instead of radiolabeled probes. Indeed,
ﬂuorescentprobesdonothavethedrawbacksofradioactivity
such as the production, delivery, and disposal of the radioac-
tive materials; the relatively short shelf life of some radionu-
clides; and the long signal acquisition times required to reach
the desired sensitivity.
To detect lanthanides by time-resolved ﬂuorescence (TR-
F) in biological assays, a sensitization is necessary. For this
purpose, organic chromophores are covalently attached to
the lanthanide chelate. The chromophore acts as an antenna
which absorbs light. This energy is transferred to the lan-
thanideexcitedstateandemittedasaﬂuorescentsignal.Since
water molecules will deactivate the lanthanide ion, an ideal
chelator willsaturate the coordination shell of the lanthanide
to prevent water from binding.
The lanthanide chelators are divided into two groups:
photoactive and nonphotoactive subclasses. A photoactive
chelatorisusefulbecauseﬁrstly,itprovidestheattachmentof
the chromophore to the lanthanide facilitating energy trans-
fer; secondly, it protects the lanthanide from coordination
with water, and it permits the attachment of other reactive
groups [8]. An alternative approach is to use nonphotoactiveColabufo Nicola Antonio et al. 3
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Figure 3: Periodic table of the elements visualising lanthanides.
Table 1: Lanthanides spectroscopic data.
Lanthanide λexcitation (nm) λemission (nm) Visible spectrum region
Tb 320 545 Green
Dy 320 572 Yellow
Eu 340 615 Red
Sm 340 642 Red
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Figure 4: Stokes’ shift.
chelators which should be stable, hydrophilic, and capable
of releasing the lanthanide after the addition of an enhance-
ment solution because in this case the ﬂuorescent chelator is
contained within this solution.
The most common chelators used in monitoring li-
gand-receptor interactions are Eu-chelates of diethylenetri-
aminetetraacetic acid (DTTA) and diethylenetriaminepen-
taacetic acid (DTPA). These chelates, used for protein label-
ing, bear an isothiocyanate group which reacts with the ε-
amino lysine residues. As depicted in Figure 5,D T T Aa n d
DTPA form a stable complex with Eu3+ by their four and ﬁve
carboxylic acid groups, respectively [9].
In most assays, to obtain a measurable TRF signal, the
lanthanide must be released from the nonphotoactive chela-
tor and must be transferred to a ﬂuorescent chelator con-
tained within the enhancement solution.
2. LANTHANIDES APPLICATIONS
The lanthanide chelates have found applications in biomed-
ical assays starting from radiotherapy based on some samar-
ium isotopes, nuclear magnetic imaging, speciﬁc cleavage
of DNA or RNA, and for sensing of various analytes and
conditions. Europium chelates have been used for sensing
several determinations, such as, pH [10], temperature [11],4 Metal-Based Drugs
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Figure 5: Eu3+ stable complexes with DTTA and DTPA.
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Figure 6: GPCRs activation cycle.
light doses, phosphate with unsaturated europium chelate
[12], glucose by time-resolving imaging [13], catalase by us-
ing tetracycline as enhancing ligand [14], neurotoxic agents
for bioterror monitoring [15], and anesthetic agents using a
dried strip reagent [16].
The photoluminescence of lanthanides is largely applied
in bioanalytical assays especially in the ﬁeld of clinical im-
munodiagnostic and for evaluating receptor-ligand interac-
tions.
Two of the most frequently applied technologies for
these purposes are the dissociation-enhanced Lanthanide
Fluorescent ImmunoAssay (DELFIA), a heterogeneous as-
say technology based on ﬂuorescence enhancement from
PerkinElmer andhomogeneous Time Resolved-Fluorescence
Resonance Energy Transfer (TR-FRET) (TRACE) from
Brahms.
DELFIA has been used for the analysis of diﬀerent bio-
chemical pathways by monitoring second messengers (cal-
cium, cAMP) for the study of G-protein and kinases activa-
tion and for cell viability determination.
3. EVALUATION OF BIOLOGICAL PATHWAYS INDUCED
BY RECEPTOR-DRUG INTERACTION
The interaction between G-protein-coupled receptors
(GPCRs) with drugs activates speciﬁc cell pathways. GPCRs,Colabufo Nicola Antonio et al. 5
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Figure 7: Signal ampliﬁcation in GPCRs activation.
also known as seven transmembrane receptors (7-TM re-
ceptors), are a large family of eukaryotic transmembrane
receptors that activate several pathways and are involved in
many diseases. GPCRs are characterized by three subunits α,
β,a n dγ; and the α subunit, in the nonactivated state, binds
GDP. GPCR stimulation by agonists leads to the dissociation
from the α subunit of the GDP and to its replacement
with GTP. This GTP-Gα complex detaches from the βγ
subunit and both of these complexes can lead to downstream
signaling. These activities are modulated in cells by GTPase
activity that allows the G-protein subunit to return to its
inactivated GDP form, hydrolyzing the GTP as depicted in
Figure 6.
The ﬁrst biochemical step is monitored by quantifying
the amount of GTP associated with the membrane. To date,
the amount of GTP produced by GPCR agonist activation
hasbeenevaluatedbybindingexperimentusing[35S]GTPγS.
Nowadays, several research groups start to use ﬂuorescent
probes to phase out radioactivity-based methods.
DELFIA GTP-binding assay is directed to the measure-
ment of GPCRs activation in membrane preparations em-
ploying a nonhydrolyzable GTP-Eu-label. This method is
a time-resolved ﬂuorometric assay based on GDP-GTP ex-
change on GαsubunitfollowedbyagonistsGPCRactivation.
As shown in Table 2, (-)-epinephrine activates α2A-ad-
renergic receptor (AR), displaying EC50 = 4.7nM and EC50
= 25nM in the Eu-GTP and [35S]GTPγS assays, respectively
[17].Superimposedresultswereobtainedby(-)-epinephrine
in β2-AR binding experiments (EC50 = 65nM and EC50 =
67nM, in the Eu-GTP and [35S]GTPγS assays, resp.).
Engstr¨ om et al. reported that the stimulation of neu-
ropeptide FF receptor (NPFF2) by (1DMe)Y8Fa resulted in
bindingofGTPtothereceptorwithEC50 =6nMforEu-GTP
and EC50 = 17nM for [35S]GTPγS[ 18]. Quinpirole, full ag-
onist at dopamine D3 receptors, displayed the same potency
(EC50 = 25nM) in both the assays [19, 20].
These results suggest that the Eu-GTP binding assay is a
reasonable alternative to the traditional [35S]GTPγS binding
assay, and that lanthanides are replacing radiolabeled tradi-
tionalmethodstocharacterizethebiologicalpathwayslinked
to receptor-drug interactions.
For a more wide application of Eu-GTP assay, this
method should be studied on several GPCRs subtypes.
Eu-GTP and [35S]GTPγS assays are usually used on
cloned cell lines and this is an advantage with respect to the
use of animal tissues. The employment of cell lines in some
cases constitutes a limit because of the low receptor expres-
sion and/or the presence of other GPCR system quenching
the signal. More speciﬁc and ampliﬁed signals (see Figure 7)
can be obtained detecting cyclic AMP (cAMP) or kinases on
living cells.
cAMP is an important second messenger mediating sev-
eralphysiologicalresponsesofneurotransmitters,hormones,
and drugs. cAMP is formed by ATP, and its intracellular
concentration is regulated by two membrane-bound en-
zymes: adenylate cyclase (AC) and phosphodiesterase. The
cAMP concentration in cells is stimulated by the activation
of adenilate cyclase, responsible for the ATP conversion into
cAMP upon ligand binding to GPCR (see Figure 8). The
ﬁrst method directly measuring the cAMP levels is based on
radioisotopes using scintillation proximity assay (SPA) tec-
nology [21–24]. An alternative method is DELFIA. This as-
say is intended for the quantitative determination of cAMP
in cell-culture samples. This method is a solid-phase time-
resolved ﬂuoroimmunoassay based on the competition be-
tween europium-labeled cAMP and cAMP of the samples
for the binding sites of cAMP-speciﬁc polyclonal antibodies
from rabbit. A second antibody, directed against rabbit IgG,
is coated to the solid phase, allowing the separation of the
antibody-bound and the free antigen. The addition of an en-
hancement solution to each sample permit the dissiociation
of the europium ions from the labeled antigen into solution,
where they form highly ﬂuorescent chelates with the com-
ponents of enhancement solution (see Figure 8). The ﬂuo-
rescence detected is inversely proportional to the amount of
cAMP in the sample.
Eu-cAMP constitutes a suitable alternative to the com-
mon radiolabeled method, [3H] cAMP, commonly used to
evaluate the accumulation of cAMP in cell line overexpress-
ing β3-AR.
As listed in Table 3,E C 50 values for three reference com-
pounds, isoproterenol, epinephrine, and norepinephrine on
β3-AR, by using [3H]cAMP [25]a r es u p e r i m p o s e d( E C 50 =
3.9, 49, and 6.3nM, resp.) with those obtained with DELFIA
(EC50 = 5.8, 31, and 5.5nM, resp.) [26].
These results suggest that also in this case, the Eu-cAMP
binding assay is a reasonable alternative to the traditional ra-
diolabeled binding assay.
Moreover, ﬂuorescent probes have also been developed
to study the activity of some protein kinases. The protein ki-
nases are a class of enzymes classiﬁed as PKCα,P K C β,a n d
PKCγ, each having a speciﬁc function. These enzymes re-
move a phosphate group from ATP and covalently attach it
to one of the three aminoacids having a free hydroxyl group
(serine, threonine, and tyrosine) chemically modifying other6 Metal-Based Drugs
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Figure 8: cAMP assay by europium measurement.
Table 2: Eu-GTP and [35S]GTPγS assays comparison.
Receptor subtypes Reference compounds Eu-GTP [35S]GTPγS
EC50,nM
α2A Epinephrine 4.7 25
β2 Epinephrine 65 67
NPFF2 (1DMe)Y8Fa 6.0 17
D3 Quinpirole 25 25
Table 3: Eu-cAMP and [3H]cAMP assays comparison.
[3H]cAMP Eu-cAMP
EC50, nM
Isoproterenol 3.9 5.8
Epinephrine 49 31
Norepinephrine 6.3 5.5
proteins.Thisphosphorylationusuallyresultsinafunctional
change of the target protein. In this way, kinases regulate
the majority of cell pathways involved in signal transduc-
tion. Protein kinases are turned on or oﬀ by phosphorylation
(sometimes by autophosphorylation) by binding of activa-
tor or inhibitor proteins. Disregulation of kinases activity is
a frequent cause of several diseases such as cancer because
kinases regulate many aspects that control the cell growth,
movement, and death. Currently, several quantitative and
sensitive nonradioactive in vitro assays such as DELFIA for
monitoring kinases activity and kinases phosphorylation are
reported in literature. Herein, the detection of Nek2, Insulin
receptor, and IKK complex is elicited.
Never In Mitosis Arrest- (NIMA-) related kinase 2, also
knownasNek2,isaserine/threoninekinaserequiredforcen-
trosome splitting and bipolar spindle formation during mi-
tosis. Nek2 phosphorylates a large centrosomal linker pro-
tein called c-NAP1 (centrosomal Nek2-associated protein 1),
which subsequently triggers the release and separation of du-
plicated centrosomes [27]. Nek2 has been demonstrated to
be concentrated primarily in the centrosomes of rapidly pro-
liferating cells. High expression of Nek2 compared to normal
tissue has been observed in lung, colon, and breast carcino-
m a sa sw e l la sB - c e l ll y m p h o m a s .D o w n r e g u l a t i o no fN e k 2
and overexpression of a kinase-defective dominant negative
enzyme result in (i) lack of centrosome separation, (ii) de-
fective spindle formation, (iii) increased apoptosis, and (iv)
decreased cell proliferation. Thus, targeting Nek2 in tumour
cells by a small molecule inhibitor may have the same phe-
notypic consequences. For this kinase, two diﬀerent DELFIA
assayshavebeendeveloped.Onemethodusesapeptideiden-
tiﬁed within c-NAP1, the other one employs Nek2 enzyme as
a substrate to monitor autophosphorylation.
DELFIA resulted in a useful assay to monitor changes
in kinases phosphorylation instead of the traditional mea-
sure of radioactive phosphate incorporation or the use ofColabufo Nicola Antonio et al. 7
phosphokinase antibodies (ELISA and Western blot). For ex-
ample, the insulin receptor (IR) is a tyrosine kinase com-
posed of two extracellular α subunits and two transmem-
brane β subunits. Insulin action starts by its binding to the
α subunits of the IR, and causes conformational changes that
lead to autophosphorylation of the β subunits and activation
of the receptor tyrosine kinase [28]. Moreover, DELFIA assay
can be easily adapted to monitor changes in the phosphory-
lation status of other cellular proteins.
IKK complex consists of two kinases, IKKα and IKKβ,
and of the regulatory nonenzymatic scaﬀold protein IKKγ
also known as NEMO (NF-κB essential modiﬁer) [29–33].
IκB phosphorylation by IKK results in the degradation of
IκB, allowing NF-κB to translocate to the nucleus and acti-
vate transcription of a variety of genes. Many studies have
indicated that activity of IKKβ is directly related to TNFα
activation, whereas IKKα is critical for the development of
the skin and skeleton during embryogenesis. To elucidate the
mechanisms by which NF-κBi sa c t i v a t e d ,i ti si m p o r t a n tt o
have an eﬀective assay to examine diﬀerent pathways. Tra-
ditionally, IKK activity has been measured by a radioactive
kinase assay utilizing [33P]ATP or [32P]ATP as a donor. For
monitoring substrates phosphorylation, DELFIA resulted in
sensitive and eﬃcient nonradioactive assays to detect multi-
ple kinase activities simultaneously, including IKK [34].
4. CONCLUSIONS
Lanthanide labels constitute a perspective in medicinal
chemistry ﬁeld for studying the activity of potential new
drugs towards GPCRs. To date, few results relating to Eu-
GTPandEu-cAMPandcomparabletothecorrespondingra-
diolabeled probes are available. With respect to radiolabeled
method, these new tools display several advantages such as
the endocellular pathways investigation in living cells, the
high sensitivity, the long shelf life, the amenability to au-
tomation, the safety, and last but not least, they represent the
novel green biochemistry. At the present, it is important to
investigate Eu-GTP and Eu-cAMP impact in several GPCRs
in order to better deﬁne the potentials of lanthanide labels in
medicinal chemistry ﬁeld.
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